Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

La descripción de la empresa se muestra en inglés.

Visitar sitio web →

Estadísticas Clave

Capitalización: $10.20M
Ratio P/E: N/A
Máximo 52 Sem.: $9.82
Mínimo 52 Sem.: $0.66
Volumen Promedio: 4.46M

Datos proporcionados por Yahoo Finance a través de yfinance. Actualizado diariamente.

Información de la Empresa

Industria: Biotecnología
Bolsa: NASDAQ
País: United States
Empleados: 5